Marker Therapeutics Reports Q1 2022 Operating and Financial Results
13 mai 2022 07h00 HE
|
Marker Therapeutics
Topline readout of Phase 2 AML trial Group 2 active disease anticipated in Q2 2022 Company plans to file INDs in lymphoma and pancreatic cancer by year end, with clinical trials to be initiated in...
Marker Therapeutics to Present Four Posters on its T Cell-Based Immunotherapies at the 2022 International Society for Cell & Gene Therapy Annual Meeting
04 mai 2022 10h30 HE
|
Marker Therapeutics
HOUSTON, May 04, 2022 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based...
Marker Therapeutics Announces Entry into Services Agreement with Wilson Wolf
26 avr. 2022 07h00 HE
|
Marker Therapeutics
HOUSTON, April 26, 2022 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based...
Marker Therapeutics Reports Fiscal Year 2021 Operating and Financial Results
17 mars 2022 17h45 HE
|
Marker Therapeutics
Enrollment of first 20 patients of the Company’s Phase 2 acute myeloid leukemia (AML) trial completed in Q4 2021 Topline readout of Group 2 active disease anticipated in Q2 2022 Company plans to...
Marker Therapeutics to Present at Two Upcoming March Investor Conferences
07 mars 2022 16h05 HE
|
Marker Therapeutics
HOUSTON, March 07, 2022 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (NASDAQ:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based...
Marker Therapeutics Announces Clinical Program Updates and Pipeline Expansion
16 févr. 2022 16h30 HE
|
Marker Therapeutics
Results from safety lead-in stage of Marker’s Phase 2 AML trial demonstrate that MT-401 was well-tolerated, eliminated measurable residual disease (MRD) in one MRD+ patient and induced epitope...
Marker Therapeutics to Host Clinical Program Update Conference Call and Webcast on Wednesday, February 16, 2022
08 févr. 2022 16h05 HE
|
Marker Therapeutics
HOUSTON, Feb. 08, 2022 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based...
Marker Therapeutics Receives FDA Orphan Drug Designation for its Multi-Antigen Targeted T Cell Therapy for Pancreatic Cancer
19 janv. 2022 16h49 HE
|
Marker Therapeutics
HOUSTON, Jan. 19, 2022 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (NASDAQ:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based...